Larotrectinib and its Impurities
Larotrectinib (tradename Vitrakvi) is a drug for the treatment of cancer.It is an inhibitor of tropomyosin kinase receptors TrkA, TrkB, and TrkC. It was discovered by Array BioPharma and licensed to Loxo Oncology in 2013. Reference standards of Larotrectinib API,and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.


(R)-N-(5-(2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-2,3-dihydro-1H-pyrrole-1-carboxamide
(R)-N-(5-(2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-2,3-dihydro-1H-pyrrole-1-carboxamide
Catalogue No.:PA 12 1481008
CAS :
NA
Molecular Formula : C21H20F2N6O
Molecular Weight : 410.43


(R)-N-(5-(2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-2,3-dihydro-1H-pyrrole-1-carboxamide
(R)-N-(5-(2-(2,5-Difluorophenyl)pyrrolidin-1-yl)pyrazolo[1,5-a]pyrimidin-3-yl)-3-oxopyrrolidine-1-carboxamide
Catalogue No.:PA 12 1481009
CAS :
2699151-02-3
Molecular Formula : C21H20F2N6O2
Molecular Weight : 426.43


(2R)-2-(2,5-Difluorophenyl)-1-(3-((S)-3-hydroxypyrrolidine-1-carboxamido)pyrazolo[1,5-a]pyrimidin-5-yl)pyrrolidine 1-oxide
(2R)-2-(2,5-Difluorophenyl)-1-(3-((S)-3-hydroxypyrrolidine-1-carboxamido)pyrazolo[1,5-a]pyrimidin-5-yl)pyrrolidine 1-oxide
Catalogue No.:PA 12 1481010
CAS :
NA
Molecular Formula : C21H22F2N6O3
Molecular Weight : 444.44